Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has announced its inclusion in a NetworkNewsAudio editorial highlighting the company's novel approach to treating multiple sclerosis (MS). The audio feature, titled “Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis,” discusses the growing need for therapies that go beyond symptom management in a global MS therapeutics market projected to reach $38.62 billion by 2030.
The feature highlights Quantum BioPharma’s lead candidate, Lucid-MS, a patented, first-in-class drug candidate designed to target the myelin sheath directly. The goal is to prevent, stop and potentially reverse its degradation, which is the underlying mechanism of multiple sclerosis. The company stated that the therapy is intended to address the significant unmet need for disease-modifying treatments that can alter the course of the disease.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum is focused on the research and development of Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models.
In addition to its MS work, Quantum invented UNBUZZD and spun out its OTC version to Unbuzzd Wellness Inc., led by industry veterans. Quantum retains ownership of 19.84% of Unbuzzd as of March 31, 2026, and is entitled to royalty payments of 7% of sales from unbuzzd until payments total $250 million, after which the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products for pharmaceutical and medical uses.
The inclusion in the NetworkNewsAudio editorial underscores the potential impact of Lucid-MS on the MS treatment landscape. With a market size expected to grow significantly, the need for disease-modifying therapies that target the root cause of MS is critical. If successful, Lucid-MS could offer a new paradigm for patients, moving beyond symptom management to altering disease progression.
